

**Centers for Disease Control and Prevention  
Model Performance Evaluation Program**

# **Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing**

**Figures Used to Summarize the  
Participant Laboratory Results  
for the May 2002 Shipment**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Centers for Disease Control and Prevention  
Public Health Practice Program Office  
Division of Laboratory Systems  
Atlanta, Georgia 30341-3717**



Use of trade names is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services.

**Report of the May 2002 Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Performance Evaluation Sample Testing Results Provided by Participant Laboratories in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).**

The production of this report was coordinated in CDC by:

Public Health Practice Program Office.....Edward L. Baker, M.D., M.P.H., Director  
Division of Laboratory Systems.....Robert Martin, Dr.P.H., Director  
.....Thomas L. Hearn, Ph.D., Deputy Director

The material in this report was developed and prepared by:

Model Performance Evaluation Program (MPEP).....G. David Cross, M.S., Chief (Acting)  
HTLV Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8091.

## **SUPPLEMENTAL INFORMATION FOR COMPREHENDING THE NUMBERS USED TO LABEL FIGURES IN THIS REPORT**

The "N=" that appears on each graph represents the number of laboratories that reported results. For some graphs, laboratories reported results using more than one test; therefore, the number of results may exceed the actual number of laboratories providing reports. In figures 1-7 and 10, the vertical axis is labeled either as frequency or percentage of results; in figures 8 and 9, this axis is labeled as percentage of reports; and in figure 11, this axis is labeled as frequency of reports. However, in all figures, the number appearing directly above or within each bar represents a frequency of results only.

**Centers for Disease Control and Prevention (CDC)  
 Model Performance Evaluation Program  
 Human T-Lymphotropic Virus Types I and II (HTLV-I/II) Testing  
 May 2002 Participant Laboratory Shipment**

**Table 1**

Panel Letter	Vial Label	CDC Donor Number	CDC Contractor Result <sup>2</sup>	Laboratory Interpretation <sup>1</sup>			
				INIT. <sup>3</sup>	FINAL <sup>4</sup>	WB	IIF
A	A1, A4	1	Negative	—	—	—	—
	A2	3	Positive, HTLV-I	—	—	—	—
	A3	2	Negative	—	—	—	—
	A5, A6	4	Positive, HTLV-II	—	—	—	—
B	B1, B6	4	Positive, HTLV-II	—	—	—	—
	B2	3	Positive, HTLV-I	—	—	—	—
	B3	2	Negative	—	—	—	—
	B4, B5	1	Negative	—	—	—	—


<sup>1</sup> Laboratory Interpretation space (to be completed by participant laboratory) provided to facilitate comparison of participant laboratory result with CDC result.

<sup>2</sup> The CDC result was obtained after composite EIA, WB, and RIPA testing, by CDC contractor, and employing the interpretation criteria of the Public Health Service Working Group.



<sup>3</sup> Initial EIA interpretation

<sup>4</sup> Final EIA interpretation


**Figure 1. Frequency of HTLV-I/II antibody test result interpretations, by sample type (reactivity), for enzyme immunoassay (EIA), Western blot (WB), and indirect immunofluorescence (IIF), reported by participant laboratories for the May 2002 shipment**




\* = Indeterminate is not an EIA interpretation option; these areas have been left blank






**Figure 2. Percentage of HTLV-I/II participant laboratories, by laboratory type, that reported EIA, WB, and IIF results to the CDC for the May 2002 shipment**





**Figure 3. Combination of HTLV-I/II antibody tests reported by participant laboratories for the May 2002 shipment**



**Figure 4. Types of HTLV-I/II antibody test kits used for enzyme immunoassay, Western blot, and indirect immunofluorescence, as reported by participant laboratories to the CDC for the May 2002 shipment**



**Figure 5. Enzyme immunoassay HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 2002 shipment**




Test Result Interpretations  
 Non-Reactive   
 Reactive



**Figure 6. Western blot HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 2002 shipment**


**SAMPLE REACTIVITY -- NEGATIVE**

**N = 12**



**SAMPLE REACTIVITY -- POSITIVE**



**N = 25**



Test Result Interpretations

■ Non-Reactive ■ Indeterminate ■ Reactive


**Figure 7. Indirect immunofluorescence HTLV-I/II antibody test results, by kit manufacturer, reported by participant laboratories for the May 2002 shipment**




Test Result Interpretations

■ Non-Reactive   ■ Indeterminate   ■ Reactive


**Figure 8. Western blot HTLV-I/II antibody band patterns reported to CDC by participant laboratories for the May 2002 shipment**



**Figure 9. Fluorescence intensity patterns, of HTLV-I/II-infected cells, for IIF results reported to CDC by participant laboratories for the May 2002 shipment**



**Figure 10. Types of 'Other' HTLV antibody test kits used and results reported by participant laboratories to the CDC for the May 2002 shipment**



**Figure 11. HTLV-I/II antigen lines reported to CDC by participant laboratories using INNO-LIA for the May 2002 shipment**

